Denileukin diftitox

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Denileukin diftitox
Clinical data
Trade namesOntak
AHFS/Drugs.comMonograph
MedlinePlusa611024
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
Intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
Elimination half-life70-80 min
Identifiers
CAS Number
IUPHAR/BPS
DrugBank
ChemSpider
  • none
UNII
ChEMBL
Chemical and physical data
FormulaC2560H4042N678O799S17
Molar mass57647.3 g/mol
 ‹See TfM›☒N☑Y (what is this?)  (verify)

Denileukin diftitox (trade name Ontak) was an antineoplastic agent, an engineered protein combining Interleukin-2 and Diphtheria toxin. Denileukin diftitox could bind to Interleukin-2 receptors[1] and introduce the diphtheria toxin into cells that express those receptors, killing the cells. In some Leukemias and Lymphomas malignant cells express these receptors, so denileukin diftitox can target these.

In 1999 Ontak was approved by the U.S. Food and Drug Administration (FDA) for treatment of Cutaneous T-cell lymphoma (CTCL).[2]

There is some evidence tying it to vision loss and in 2006 the FDA added a black box warning to the drug's label.[2]

In 2014 marketing of Ontak was discontinued in the US.[3]

References[edit]

  1. ^ Turturro F (2007). "Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders". Expert Rev Anticancer Ther. 7 (1): 11–7. doi:10.1586/14737140.7.1.11. PMID 17187516.
  2. ^ a b FDA Page Last Updated: May 11, 2009 Changes in the Ontak (denileukin diftitiox) Package Insert to Include a Description of Ophthalmologic Adverse Events
  3. ^ "FDA Drug Shortages". FDA. 31 January 2014. Retrieved 3 July 2017.

External links[edit]